President Donald Trump struck deals with Eli Lilly and Novo Nordisk to reduce prices of weight loss drugs like Wegovy and Zepbound to $50-$350 monthly starting next year. Medicare will cover GLP-1 drugs for obesity in mid-2026, allowing more patients to qualify. Medicaid may also offer these drugs at reduced prices.

Read more at CNBC: Trump strikes deal with Eli Lilly, Novo Nordisk